Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 1 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Alkermes, Inc.
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 1 diabetes

• Non smoker

• Normal lung function

Exclusion Criteria:

• Significant pulmonary, hepatic, or renal disease

• Severe congestive heart failure

• Active malignancy

• Systemic glucocorticoid therapy